



Business Results First Three Months of the Fiscal Year Ending March 31, 2026

Sysmex Corporation
August 6, 2025

**Together for a better
healthcare journey**

Disclaimer

- This material contains forward-looking statements about the Sysmex Group. These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.
- The information on products and other matters contained herein is not intended as advertising or medical advice, whether or not regulatory approval has been obtained.
- The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.

Index

- 1. Executive Summary**
- 2. Business Results, First Three Months of the Fiscal Year Ending March 31, 2026**
- 3. Growth Strategy Progress**
- 4. Financial Forecast for the Fiscal Year Ending March 31, 2026**

(Appendix)

- Results against Sustainability Targets for the Fiscal Year Ended March 31, 2025 (Preliminary)

1. Executive Summary

Executive Summary



Results for the First Three Months

- **Decline in sales and profit year on year due to yen appreciation and transition to a new core system in Japan**

YoY comparison Net sales: -5.6%; operating profit: -36.5%; profit attributable to owners of the parent: -58.7%

- Restricted order intake due to system transition Impact: Net sales ¥-3.3 billion, Gross profit ¥-2.4 billion
- Increased amortization associated with the operation of the core system in Japan.

Impact: SG&A (depreciation) ¥+0.6 billion

Impact summary of transition to a new core system : Net Sales ¥-3.3 billion, Operating profit ¥-3.0 billion Reflected in initial financial forecast

- Inventory revaluation in overseas Impact: Operating profit ¥-1.7 billion Not reflected in initial financial forecast

- **Net Sales increased YoY on a local currency basis, excluding Japan and China**

- In China, the market environment got worse due to government-driven healthcare cost control policies, resulting in a year-on-year decline of -5%* on a local currency base

Financial Forecast for the Fiscal Year Ending March 31, 2026

- First half: Revised our plan to reflect the following impacts
 - Delayed recovery from the impact of the core system transition in Japan
 - Potential revenue decline in China (estimated impact: approximately –5 to –10% YoY on a local currency basis).
 - Impact of the revaluation of overseas inventories recorded in the first quarter
- Full year:

In addition to strengthening sales in each region, we **expect to achieve our full-year targets** by adding new growth drivers.

 - Americas : XRTM-Series/CNTM-series contribution in 2nd half
 - China : Full-year results are expected to be flat YoY on a local currency basis by strengthening sales and adding new product portfolio
 - Japan : Addition of product portfolio through collaboration with other companies
- New growth elements in the diagnostics business : Under progress

2.


**Business Results, First Three Months of the
Fiscal Year Ending March 31, 2026**

Financial Highlights (Year on Year)



(Billions of yen)	First three months of fiscal year ending March 31, 2026		First three months of fiscal year ended March 31, 2025		YoY (Previous period = 100%)
	Results	Ratio	Results	Ratio	
Net sales	105.7	100%	111.9	100%	94.4%
Cost of sales	51.2	48.5%	51.9	46.4%	98.8%
SG&A expenses	38.2	36.2%	36.0	32.2%	106.3%
R&D expenses	6.4	6.1%	7.3	6.6%	87.1%
Other income (expenses)	0.8	0.8%	0.07	0.1%	-
Operating profit	10.6	10.1%	16.7	15.0%	63.5%
Profit attributable to owners of the parent	4.5	4.3%	11.0	9.9%	41.3%

- **Net sales:** Sales were down due to yen appreciation and the impact of the transition of the core system in Japan.
- **Operating profit:** Profit declined due to the impact of the transition to the new core system and other factors.
 - ✓ **Impact of transition to the new core system :** Sales: - ¥3.3 billion, SG&A: + ¥0.6 billion, operating profit: - ¥3.0 billion
 - ✓ **Impact of Inventory revaluation in overseas :** operating profit: - ¥1.7 billion
 - ✓ **Forex impact:** Sales: - ¥5.5 billion, SG&A: - ¥1.34 billion; operating profit: +¥0.71 billion
 - ✓ **At the rates prevailing one year earlier:** Sales down 0.6%; SG&A up 10.1%; operating profit down 40.8%
- **Profit attributable to owners of the parent:** Profit fell 58.7%:
Foreign exchange gain (loss): Loss of ¥1.50 billion (YoY down ¥2.89 billion)




	First three months of fiscal year ending March 31, 2026	First three months of fiscal year ended March 31, 2025
1USD	¥144.6	¥155.9
1EUR	¥163.8	¥167.9
1CNY	¥20.0	¥21.5

Breakdown of Net Sales (by Business and Field)

Sales by Business and Field

(Billions of yen)



Note: Sales by field exclude the impact of system changes in Japan.

Despite the impact of yen appreciation and system changes, sales were favorable in the urinalysis and hemostasis field.

(Billions of yen)	First three months of fiscal year ending March 31, 2026		YoY (Previous period = 100%)	
	Results	Ratio	Yen basis	Excluding the core system transition, FX impact
Net sales	105.7	100.0%	94.4%	102.4%
Hematology	64.8	61.3%	91.7%	98.7%
FCM	0.5	0.6%	73.1%	76.8%
Urinalysis	9.7	9.2%	109.1%	118.9%
Hemostasis	14.6	13.9%	100.7%	112.3%
Immunochemistry	4.0	3.8%	86.0%	101.7%
Clinical chemistry	0.6	0.6%	73.4%	83.9%
Life science	5.1	4.8%	97.6%	101.0%
Others	5.2	4.9%	103.9%	107.2%
Diagnostics business	104.8	99.1%	94.6%	102.6%
Medical robotics business	0.9	0.9%	79.7%	79.7%

Breakdown of Net Sales (by Destination and Product Type)

Net Sales increased in YoY on a local currency basis, excluding Japan and China

(Billions of yen)	First three months of fiscal year ending March 31, 2026		YoY (Previous period = 100%)	
	Results	Ratio	Yen basis	Local currency basis
Net sales	105.7	100.0%	94.4%	99.4%*
Americas	30.2	28.6%	95.5%	102.9%
EMEA	35.1	33.2%	101.2%	103.7%
China	17.2	16.4%	88.5%	95.1%
AP	12.0	11.4%	98.0%	103.5%*
Japan	11.0	10.4%	80.3%	-
Instruments	19.4	18.4%	93.2%	98.0%*
Reagents	66.7	63.1%	94.3%	99.3%*
Services	15.6	14.8%	96.3%	101.8%*
Others	3.9	3.7%	95.2%	98.2%*


*Year-on-year increase on a yen basis, excluding the impact of exchange rate fluctuations

Major Reasons for Changes by Destination


Note: On a local currency basis

Americas	<ul style="list-style-type: none"> Although sales of instruments for Central and South America declined due to strong performance in the previous year, growth in the hematology and urinalysis fields in North America led to an overall increase in sales.
EMEA	<ul style="list-style-type: none"> Despite a decline in sales in countries such as Turkey and Saudi Arabia due to geopolitical factors in the Middle East, strong performance in major markets resulted in overall sales growth.
China	<ul style="list-style-type: none"> Under a challenging environment caused by government-led healthcare cost containment policies, enhanced sales initiatives helped limit the year-on-year sales decline to 5%.
AP	<ul style="list-style-type: none"> Reagent sales in the urinalysis and hemostasis fields grew, resulting in local-currency-based sales growth; however, sales declined in yen terms due to the impact of exchange fluctuations in the AP.
Japan	<ul style="list-style-type: none"> Due to the implementation of order restrictions accompanying the core system transition, reagent sales significantly declined.

By Destination



By Product Type



Information by Destination (Americas)

(Million USD)	First three months of fiscal year ending March 31, 2026	First three months of fiscal year ended March 31, 2025	YoY (Previous period = 100%) Local currency basis	Yen basis
Net sales	208.9	202.9	102.9%	95.5%
Instruments	41.5	43.2	96.0%	89.1%
Reagents	106.6	102.9	103.6%	96.1%
Services, others	60.7	56.8	106.9%	99.2%

Although sales of instruments for Central and South America declined due to strong performance in the previous year, growth in the hematology and urinalysis fields in North America led to an overall increase in sales.


● Instruments

- ✓ Sales declined due to comparison with the strong performance in Central and South America in the previous year.
- ✓ Sales in the urinalysis field grew owing to enhanced promotional efforts, and performance in the hemostasis field expanded in the United States following the shift to direct sales.

● Reagents

- ✓ Sales increased in the solidly performing hematology, urinalysis, and immunochemistry fields, which performed well.

Note: Amyloid β reagent sales : USD 0.5 million (YoY +32%).



Information by Destination (EMEA)

(Million EUR)	First three months of fiscal year ending March 31, 2026	First three months of fiscal year ended March 31, 2025	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	214.6	206.8	103.7%	101.2%
Instruments	47.2	41.9	112.5%	109.8%
Reagents	134.4	131.9	101.9%	99.4%
Services, others	32.9	32.9	100.0%	97.5%


Despite a decline in sales in countries such as Turkey and Saudi Arabia due to geopolitical factors in the Middle East, strong performance in major markets resulted in overall sales growth.

● Instruments

- ✓ Sales increased as the XR-Series performed strongly in France, northern Europe, and other markets.
- ✓ In Italy, the transition to direct sales progressed smoothly, leading to growth in both the hematology and urinalysis fields.

● Reagents

- ✓ Although sales declined in Turkey and Saudi Arabia, the hemostasis field saw sales growth in Germany and France thanks to the effects of direct sales. The urinalysis field also performed well across the region, resulting in overall sales growth.



Information by Destination (China)

(Million CNY)	First three months of fiscal year ending March 31, 2026	First three months of fiscal year ended March 31, 2025	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	864.0	908.8	95.1%	88.5%
Instruments	87.6	97.8	89.5%	83.3%
Reagents	702.9	720.9	97.5%	90.7%
Services, others	73.3	89.9	81.5%	75.9%

Under a challenging environment caused by government-led healthcare cost containment policies, enhanced sales initiatives helped limit the year-on-year sales decline to 5%.


● Instruments

- ✓ Sales in the hematology field declined due to the strong performance in the same period last year of models targeting mid- and lower-end markets.
- ✓ The urinalysis, hemostasis, and immunochemistry fields delivered double-digit growth, driven by strong sales of locally manufactured instruments.

● Reagents

- ✓ Sales in the hematology field declined due to factors such as the exclusion of CRP* testing from initial examinations.
- ✓ Despite the impact of cost-containment policies, sales in the urinalysis, hemostasis, and immunochemistry fields grew, supported by expansion of the installed instrument base and growing adoption of test parameters.

Note: CRP test reagents are classified under the hematology field.



Reference | Current Situation on and Measures for Addressing China's Policies for Curtailing Medical Expenses



Government-led policies to curtail medical expenditures

● Reduction in test prices

✓ Volume-based procurement (VBP)

Hospital procurement prices for reagents—especially in the immunochemistry field, where unit prices are high and testing volumes are large—have been reduced by approximately 50%. VBP is being implemented across provincial boundaries.

✓ Unification of test pricing

A policy to standardize test prices nationwide, which currently vary by province. The approach is to reduce prices in high-cost provinces and establish unified ceiling prices. Immunochemistry and diabetes-related tests are currently subject to this measure.

● Optimization of testing volumes

✓ Inter-facility sharing of test data

Aimed at curbing retesting during patient transfers. Nationwide implementation targeted by the end of 2030.

✓ Restrictions on bundled testing / diagnosis related groups (DRG)

Stricter reimbursement rules are being applied to optimize test items, such as removing CRP testing from basic initial hematology panels.

Tough market environment persists


Sysmex's current situation and response

● Current situation

- ✓ Despite the challenging environment, due to the exclusion of set tests, the number of CRP tests decreased, but testing volumes in hematology have slightly declined.
- ✓ Sales in urinalysis, hemostasis, and immunochemistry have increased due to the introduction of locally produced instruments—but the situation remains unpredictable.

A first-half sales risk of –5 to –10% is assumed.

Number of hematology tests in China




● Response

- ✓ **Strengthening direct outreach** to target institutions to win business from competitors
- ✓ Promoting **proposals for fully automated system products** that support cost-efficiency improvements for medical institutions
- ✓ **Expanding our product portfolio**

Information by Destination (AP)

(Billions of yen)	First three months of fiscal year ending March 31, 2026	First three months of fiscal year ended March 31, 2025	YoY (Previous period = 100%) Yen basis
Net sales	12.0	12.3	98.0% (103.5%)*
Diagnostics business	12.0	12.3	97.6%
Instruments	2.3	2.5	90.7%
Reagents	8.6	8.4	103.1%
Services, others	1.0	1.3	77.1%
Medical robotics business	0.04	-	-

*Note: Figures in parentheses exclude the impact of exchange rate fluctuations.



Reagent sales in the urinalysis and hemostasis fields grew, resulting in local-currency-based sales growth; however, sales declined in yen terms due to the impact of exchange fluctuations and other factors occurring in the AP.

Diagnostics business

● Instruments

- ✓ Although sales grew significantly in India, overall instrument sales declined due to factors such as budget constraints for medical equipment in Indonesia.

● Reagents

- ✓ Sales increased, owing to strong performance in the urinalysis and hemostasis fields. Sales in the hematology field fell slightly, partly due to comparison with strong performance in India during the same period last year.

Medical robotics business

- ✓ The number of surgeries continued to grow steadily, with over 100 procedures conducted in Singapore and more than 80 in Malaysia.

Information by Destination (Japan)

(Billions of yen)	First three months of fiscal year ending March 31, 2026	First three months of fiscal year ended March 31, 2025	YoY (Previous period = 100%) Yen basis
Net sales	11.0	13.7	80.3%
Diagnostics business	10.1	12.5	80.7%
Instruments	1.5	1.6	93.2%
Reagents	6.6	8.6	76.0%
Services, others	1.9	2.2	89.4%
Medical robotics business	0.8	1.1	76.0%

Due to the implementation of order restrictions accompanying the core system transition, reagent sales significantly declined, led to an overall decrease in sales.

Diagnostics business

● Instruments


- ✓ Despite significant growth in the hemostasis field, sales declined due to factors such as a reactionary drop following strong instrument sales in the hematology field in the previous fiscal year.

● Reagents


- ✓ Sales declined due to restrictions on orders in key fields during the transition to the new core system.

Medical robotics business

- ✓ Units installed in Q1: 1; cumulative total: 87
- ✓ As the number of installations and surgical procedures increased, sales of services and consumables (such as forceps) increased steadily.



Breakdown of Operating Profit



Note: Figures and comments below exclude the impact of exchange rates.

- Temporary factors : - ¥4.82 billion
 - ✓ Change in gross profit due to order restrictions associated with the system transition : - ¥2.4billion
 - ✓ Increased amortization due to the operation of the core system : - ¥0.67 billion
 - ✓ Impact of inventory revaluation on a consolidated basis: - ¥1.75 billion
- Impact of changes in the cost of sales ratio: - ¥0.91 billion (0.9pt deterioration)
 - ✓ Positive factor: Improve logistics costs, 0.4 pt
 - ✓ Negative factors: Worsening service costs, 1.0pt
- Higher SG&A expenses: - ¥2.95 billion
 - ✓ Labor costs worsened by approx. ¥1.5 billion due an increase in personnel in line with expansion of the direct sales area and a rise in unit labor costs.
 - ✓ Other costs rose by approx. ¥1.1 billion owing to an increase in scale and sales promotion activities.
- Lower R&D expenses: ¥0.94 billion
 - ✓ Despite continued investment in product development, the completion of the hemostasis project and the refinement of R&D themes through the pivot in the life sciences field led to a decrease.
- Other operating income: ¥0.81 billion
- FX impact: + ¥0.71 billion

3. **Growth Strategy Progress**

Reinforcement of Existing Businesses, Emerging Market Strategies,
Expansion of New Businesses

Three Growth Strategies: Reinforcement of Existing Businesses

Hematology Field

✓ Progress

- **Obtained US regulatory approval for XR-Series (Late June)**
- Favorable ongoing growth in EMEA

✓ Expectations for the fiscal year ending March 31, 2026

- Launch of the XR-Series in the Americas



XR-Series Automated Hematology Analyzer

Hemostasis Field

✓ Progress

- **Obtained US regulatory approval for CN-Series (Early June)**
- Favorable growth in reagent sales in key EMEA countries
- Progress on Blood Scient introduction in EMEA, Japan, and South Korea

✓ Expectations for the fiscal year ending March 31, 2026

- Launch of the CN-Series in the Americas



CN-Series Automated
Blood Coagulation Analyzer

As the global No.1 in hematology and hemostasis,
we have launched new products in the United States, the largest market in the world.

Reinforcement of Existing Businesses: Blood Biomarkers Related to Alzheimer's Disease



Promoting the development of A β -based biomarkers with strong potential—
from pre-onset through mild cognitive impairment.

ApoE

- Sysmex obtained manufacturing and marketing approval for Japan's first assay kit assessing the risk of adverse reactions to anti-amyloid β antibody drugs for Alzheimer's disease (June 2025)

Amyloid β (A β 42/40 ratio)


- Listed as the only amyloid beta reagent in the screening guidelines presented at the Alzheimer's Association International Conference thanks to high sensitivity and specificity (July 2025)

p-tau217, 205

- p-tau217 : Currently preparing for releasing by March 2026
- p-tau205 : Development promoted with increased priority following p-tau 217

**Confirmed high correlation with reference method
(mass spectrometry) confirmed**

Presented at the International Conference on Alzheimer's and Parkinson's Disease (April 2025)



<https://aaic.alz.org/>




<https://adpd2025.kenes.com/>

Three Growth Strategies: Emerging Market Strategies


Current-Year Growth Drivers

Future Initiatives



- Increase in bidding opportunities due to the launch of locally produced products aligned with the Make in India initiative
- Expansion of sales areas within India through strengthened support infrastructure

Further reinforcement of the foundation in anticipation of market expansion through product lineup enhancement at the new production base in India




- Market growth driven by increased investment in healthcare infrastructure
- Steady growth in reagent sales supported by expansion in the installed instrument base

Construction of a new reagent production facility in Brazil to support a stable supply system for the rapidly growing Central and South American market



Illustration of new production site in Brazil



- Market expansion in Saudi Arabia driven by increased investment in healthcare infrastructure
- Expanded hemostasis sales in the Middle East through the application of Blood Science



Maximizing business in East Africa through direct sales operations in Kenya

*META: Middle East, Turkey, Africa


Three Growth Strategies: Expansion of New Businesses—Medical Robotics business



Steady progress leading to a new growth phase



hinotori Surgical Robot System



- ✓ **Covers over 90% of robotic-assisted surgeries performed in Japan**, and the number of installations and procedures is increasing steadily
- ✓ Medicaroid expected to **become profitable** on an annual basis in the **fiscal year ending March 31, 2026**

Three Growth Strategies: Expansion of New Businesses - Regenerative and Cellular Medicine and others

Regenerative and Cellular

- **Contributing to the provision of safer and higher quality regenerative cell therapy by utilizing our existing technologies**
 - ✓ Applying our inspection technology to quality control testing for regenerative cell therapy
Plans to implement quality control for Megakaryon's iPS cell-derived platelet preparations
 - ✓ In partnership with Gaudi Clinical, we offer cell manufacturing services for medical institutions. Contributing to safe, high-quality treatment through our inspections



RF-500 flow cytometer
for research use



XR-1000 Automated
Hematology analyzer



Automated Immunoassay
System HISCL™-800

Digital Solution

- **Accelerating chronic disease and cancer prevention support through AI and medical data (agreement reached with Nippon Life Insurance Company)**
 - ✓ The two companies conducted feasibility studies on the development of disease risk assessment models for chronic diseases, cancer, these studies yielded favorable results.
 - ✓ To define multiple specific research themes aimed at developing disease risk assessment models and jointly promote new initiatives using digital solutions in the healthcare field.

4. Financial Forecast for the Fiscal Year Ending March 31, 2026

Impact of US Reciprocal Tariffs

The impact on cost of sales is expected to remain within the estimated range of approximately ¥3.0–4.0 billion annually.

Initial Assumptions

- Reciprocal tariff: Additional tariff rate of 10%
Target: Mainly instruments bound for the US
- Additional 25% on steel and aluminum products
Target: Mainly Japan-made parts containing aluminum and steel
- Impact of retaliatory tariffs imposed by other countries

Revised Assumptions (After August 1)

- Reciprocal tariff: Additional tariff rate of **15%**
Target: Mainly instruments bound for the US
- Additional **50%** on steel and aluminum products
Target: Mainly Japan-made parts containing aluminum and steel
- Impact of retaliatory tariffs imposed by other countries

The impact in Q1 is minor. The increase in tariffs is expected to remain within the initial annual forecast, even after considering measures such as inventory buildup, supply chain review, and manufacturing process review, price adjustments.

Financial Forecast for the Fiscal Year Ending March 31, 2026



First half: We have revised our plan to reflect delayed recovery in Japan, potential revenue decline in China and Impact of the revaluation of overseas inventories recorded in the first quarter.
Full year: The realization of new growth element in the diagnostics business, and additional growth initiatives such as portfolio expansion. Full-year targets are expected to be achieved.

(Billions of yen)	Initial forecast 1H of fiscal year ending March 31, 2026 (April–September)		Revised forecast 1H of fiscal year ending March 31, 2026 (April–September)			*Unchanged Fiscal year ending March 31, 2026 (April–March)		
				Ratio	Vs. initial forecast		Ratio	YoY (Previous period = 100%)
Net sales	252.5	100.0%	240.0	100.0%	△ 12.5	535.0	100.0%	+5.2%
Operating profit	44.5	17.6%	36.0	15.0%	△ 8.5	91.5	17.1%	+4.5%

● Assumed Exchange Rates

*Unchanged from May 2025

	Full year (Announced May 2025)
1 USD	¥142.0
1 EUR	¥160.0
1 CNY	¥19.5

● Exchange Rate Sensitivity (Year)

*Unchanged from May 2025

	Net sales	Operating profit
USD	¥0.81 billion	¥0.11 billion
EUR	¥0.6 billion	¥0.05 billion
CNY*	¥0.58 billion	¥0.43 billion

*Exchange rate sensitivity: 0.1 yen basis

(Appendix)

Sustainability Targets

Results for the Fiscal Year Ended March 31, 2025



Creating new value for a healthy society

• The items whose targets are displayed as “-” are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025	Fiscal year ending March 31, 2026
Resolution of medical issues through innovation	Number of hematology tests	3,325 million	3,322 million	-
	Hematology market share ^{*1}	53.0%	54.6%	-
	Number of cases with surgical support robot	2,903	5,209	-
	Number of patents	3,868	3,337	-
	Number of new patents	200	182	-
	Number of patent genomes analyzed ^{*2}	1.6 thousand	1.8 thousand	-
	Number of breast cancer tests using the OSNA TM method	52 thousand	53 thousand	-
Improvement in accessibility to healthcare	Sales in emerging and developing markets	¥164.6 billion	¥179.5 billion	-

Providing responsible products, services, and solutions

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025	Fiscal year ending March 31, 2026
Pursuit of quality and trust	Number of recalls ^{*2,*4}	4	6	-
	Number of FDA warning letters	0	0	-
Strengthening of supply chain management	CSR survey response rate (primary suppliers in Japan and overseas)	95%	95%	90%
	Number of training sessions for suppliers (Japan) ^{*3}	6	6	5
	Third-party certification rate of suppliers (primary, Japan) ^{*3}	88%	89%	-

^{*1} Source: Clearstate and Sysmex's assumptions ^{*2} Target: Sysmex Group in Japan ^{*3} Target: Sysmex Corporation on a non-consolidated basis

^{*4} The previous year's figure has been revised, owing to a change in calculation method.

Sustainability Targets

Results for the Fiscal Year Ended March 31, 2025



Reducing environmental impacts

- Results for the fiscal year ended March 31, 2025 are preliminary.
- The items whose targets are displayed as “-” are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025	Fiscal year ending March 31, 2026
Resource circulation in product life cycle	Zero product losses	0.40%	0.40%	0.18%
	Recycling of containers and packing and utilization of environment compliance materials	43%	62%	60.0%
	Reduction of greenhouse gas emissions (Scope 3)* ¹	Cut 4%	Cut 1%	Cut 10%
	Supplier engagement ratio	—	40%	—
	Reduction of packaging and labeling materials* ²	Cut 9%	Cut 4%	—
Reduction in environmental burden through business activities	Reduction of greenhouse gas emissions (Scopes 1, 2)* ¹	Cut 29%	Cut 33%	Cut 40%
	Ratio of renewable energy	69%	72%	75%
	Reduction of using energy per employee* ¹	Cut 8%	Cut 7 %	Cut 3%
	Reduction of water consumption (main reagent factories)* ¹	Up 2pt* ³	Cut 31pt	Cut 23pt
	Reduction of total waste* ¹	Cut 32%	Cut 33%	Cut 5%
	Ratio of product waste to sales	0.4%	0.5%	—

Scope 1: GHG emitted directly by company facilities, factories, and fleet
 Scope 2: GHG emitted indirectly by the company due to energy use
 Scope 3: GHG emitted throughout the value chain in relation to products and services

*1 Base year: Fiscal year ended March 31, 2023

*2 Base year: Fiscal year ended March 31, 2020

*3 The previous year's figure has been revised, owing to a change in calculation method

Sustainability Targets

Results for the Fiscal Year Ended March 31, 2025



Strengthening governance

• The items whose targets are displayed as “-” are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025	Fiscal year ending March 31, 2026
Corporate governance	Number of meetings with investors and analysts ^{*2}	723	753	-
Compliance	Number of internal reports	26	17	-
	Number of unethical incidents	15	19	-
Risk management	Number of information security trainees ^{*1}	11,097	27,060	-
	Participation rate in disaster drills ^{*1}	-	89.5%	-

*1 Target: Sysmex Group in Japan

*2 Target: Sysmex Corporation on a non-consolidated basis

Sustainability Targets

Results for the Fiscal Year Ended March 31, 2025



Creating an attractive workplace

• The items whose targets are displayed as “-” are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025	Fiscal year ending March 31, 2026
Increased engagement	Engagement score	75%	76%	75%
	Turnover ratio	7.7%	8.0%	10% or less
	Self-turnover rate	5.6%	5.6%	—
	Return rate from parental leave ^{*2}	99%	99%	—
	Percentage of men taking childcare leave ^{*2}	61%	77%	65% or more
Promotion of diversity, equity and inclusion	Female managers ratio	19.2%	18.7%	20% or more
	Female next-generation managers ratio	34.0%	34.0%	—
	Female employees rate	41.5%	41.1%	—
	Percentage of mid-career recruitment in managerial and professional positions ^{*2}	39.8%	38.6%	—
	Male/female percentage among recruits (new graduates and mid-career) ^{*2}	Newly graduated: 45.2% Mid-career: 25.8%	Newly graduated: 43.0% Mid-career: 36.5%	—
	Percentage of women and non-Japanese nationals in management ^{*2}	Women: 8.3% Non-Japanese: 16.7%	Women: 8.3% Non-Japanese: 16.7%	—
	Percentage of women in management	13.5%	14.8%	—
	Salary inequality in managerial and professional positions (total compensation) ^{*2}	94.0%	96.2%	—
	Salary inequality general employees (total compensation) ^{*2}	82.1%	84.7%	—
	Percentage of employees with disabilities ^{*1}	2.38%	2.69%	2.65% or more

*1 Target: Sysmex Group in Japan

*2 Target: Sysmex Corporation on a non-consolidated basis

Sustainability Targets

Results for the Fiscal Year Ended March 31, 2025



Creating an attractive workplace

• The items whose targets are displayed as “-” are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025	Fiscal year ending March 31, 2026
Development of human resources	Training time per employee	24.4 hours	24.7 hours	40.0 hours
	Value-added productivity (non-consolidated)* ²	¥14,760	¥15,042	—
	Value-added productivity (Group)	¥19.97 million	¥21.44 million	¥22.50 million
	Human resources development investment (non-consolidated)* ²	¥241 million	¥261 million	¥252 million
	Human resources development investment (Group)	¥369 million	¥595 million	—
	Participation rate in training (non-consolidated)* ²	100%	100%	90% or more
	Participation rate in training (Group)	97%	96%	—
	Success plan effectiveness Rate* ²	100%	92.3%	—
	Succession coverage rate* ²	311.0%	289.5%	—
Promotion of health and occupational safety	Total annual working hours* ^{1,*3}	1,995 hours	1,993 hours	1,980 hours
	Percentage of days of paid leave taken* ¹	74.6%	67.1%	75% or more
	Lost-time injury frequency rate* ¹	0.78	0.71	Less than 0.5
	Lost work day rate* ¹	0.07	0.05	Less than 0.05

*1 Target: Sysmex Group in Japan

*2 Target: Sysmex Corporation on a non-consolidated basis

*3 The previous year's figure has been revised, owing to a change in calculation method

Reference: Topics (April–July 2025)

Reinforcement of Existing Businesses

- Sysmex's CN-6000 Automated Blood Coagulation Analyzer and XR-Series Automated Hematology Analyzer Receive U.S. FDA 510(k) Clearance
- Sysmex Establishes Subsidiaries in Kenya and Greece (EMEA)
- Sysmex Group's New Manufacturing Base in India Begins Full-Scale Operations and Launches "Make in India" Products (AP)
- Sysmex Expands and Relocates Production Base in Brazil (Americas)

Expansion of New Businesses

- Demonstration of Remote Surgery Using the hinotori Surgical Robot System Successfully Performed Between Europe and Japan
- Regenerative and Cellular Medicine: Sysmex and Gaudi Clinical Agree on a Business Collaboration and Capital Alliance (Japan)
- Sysmex and Nissay Agree to Collaborate in Healthcare Field (Japan)

Sustainability

- Sysmex Introduces Performance-Linked Stock Compensation Plan
- Sysmex Selected by US *TIME* Magazine as One of the World's Most Sustainable Companies of 2025



Together for a better
healthcare journey